Eisai, Arena to launch obesity drug next month

05/9/2013 | PharmaTimes (U.K.)

Eisai and Arena Pharmaceuticals plan to launch their antiobesity drug Belviq, or lorcaserin, in the U.S. next month following the drug's classification as a Schedule IV controlled substance. Belviq was approved by the FDA last year for chronic weight management in obese adults who suffer from at least one weight-related condition. The launch triggers the payment of a $65 million milestone fee from Eisai to Arena.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY